Author Archives: Joana Fernandes, PhD

Reata Tests Bardoxolone Methyl as Possible Treatment for Loss of Kidney Activity in Alport Syndrome

Reata Pharmaceuticals is investigating bardoxolone methyl as a potential treatment for chronic kidney disease (CKD) triggered by Alport syndrome. The CARDINAL (NCT03019185) Phase 2/3 clinical trial — which is currently recruiting patients — aims to determine the safety, tolerability and effectiveness of oral bardoxolone methyl in slowing, halting and possibly…

Timely Treatment of Kidney Failure in Alport Patients Seen to Prevent Kidney Disease Progression

Timely treatment of kidney failure in Alport patients with different mutations can prevent progression to chronic kidney disease and end-stage failure, researchers reported. The study, “Prospective Study On The Potential Of RAAS Blockade To Halt Renal Disease In Alport Syndrome Patients With Heterozygous Mutations,” was published in the journal Pediatric…

Create your own user feedback survey